Oxygen Of The Saccharide Radical Bonded Directly To A Polycyclo Ring System Of Four Carbocyclic Rings (e.g., Daunomycin, Etc.) Patents (Class 514/34)
-
Publication number: 20130108582Abstract: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:Type: ApplicationFiled: May 18, 2012Publication date: May 2, 2013Inventors: Alfredo C. Castro, Michael J. Grogan, William Matsui, Karen J. McGovern, Martin R. Tremblay
-
Publication number: 20130109628Abstract: The disclosure relates to microRNAs (miRNAs) for the prophylaxis and/or treatment of neoplasia. The disclosure relates in particular to sequence corresponding to miR2 and the miR-548 family, including precursors, mature forms, fragments, and combinations thereof for the prophylaxis and/or treatment of neoplasias, particularly lung, stomach, and cervical cancer, alone or in combination with additional cancer treatments and therapeutics.Type: ApplicationFiled: July 14, 2011Publication date: May 2, 2013Applicant: EMORY UNIVERSITYInventors: Ya Wang, Baicheng Hu, Walter J. Curran
-
Patent number: 8431143Abstract: A titanium dioxide composite is provided that can be stably dispersed in an aqueous solvent and easily administered into a living body, such as human, and allows elimination of the drug efficacy of a pharmaceutical compound supported thereon by light irradiation and a dispersion thereof. A composite is used in which a pharmaceutical compound is bound to titanium dioxide having photocatalytic activity through a hydrophilic polymer. The composite is stable in an aqueous solvent and easily administered into a living body, and adverse drug reactions of the pharmaceutical compound can be reduced by administering the composite into the body and irradiating the composite with a light to photoexcite the titanium dioxide to decompose the pharmaceutical compound in a region where the drug efficacy of the pharmaceutical composition is not required.Type: GrantFiled: September 24, 2010Date of Patent: April 30, 2013Assignee: Toto Ltd.Inventors: Shuji Sonezaki, Koki Kanehira, Yumi Ogami, Toshiaki Banzai, Yoshinobu Kubota
-
Publication number: 20130101680Abstract: The present invention relates to a method of treating pancreatic cancer in a subject in need thereof by administering an effective amount of a composition containing (A) tegafur and (B) gimeracil in conjunction with radiotherapy.Type: ApplicationFiled: December 17, 2012Publication date: April 25, 2013Inventor: Masakazu FUKUSHIMA
-
Publication number: 20130102553Abstract: The invention relates to therapeutic agents for use in the prevention or treatment of Alzheimer's disease. In particular the invention relates to use of inhibitors of cell cycle reentry and progression to the G1/S transition or inhibitors of progression of the cell cycle through the G1/S transition point in the prevention or treatment of Alzheimer's disease.Type: ApplicationFiled: November 30, 2012Publication date: April 25, 2013Applicant: ISIS INNOVATION LTD.Inventor: ISIS INNOVATION LTD.
-
Publication number: 20130101666Abstract: A liposome including a lipid bilayer, an elastin-like polypeptide (ELP) conjugated to a hydrophobic moiety; a chemosensitizer; and an anticancer agent, a pharmaceutical composition including the same, and a method of delivering a chemosensitizer and an anticancer agent to a target site of a subject by using the liposome.Type: ApplicationFiled: October 19, 2012Publication date: April 25, 2013Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventor: Samsung Electronics Co., Ltd.
-
Publication number: 20130095100Abstract: This invention relates to novel 2-{6-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-2-methyl-pyrimidin-4-ylamino}-thiazole-5-carboxylic acid (2-chloro-6-methyl-phenyl)-amide derivatives, and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by the inhibition of kinases including Src-kinase and Bcr-Abl kinase.Type: ApplicationFiled: December 6, 2012Publication date: April 18, 2013Applicant: Concert Pharmaceuticals, Inc.Inventor: Concert Pharmaceuticals, Inc.
-
Publication number: 20130095170Abstract: Methods and systems for identifying and treating a patient suspected of having a tumor susceptible to growth inhibition by anti-progestins are provided. The degree of focal distribution of the progesterone receptor can be used to identify tumors susceptible to treatment with anti-progestin therapy.Type: ApplicationFiled: October 4, 2012Publication date: April 18, 2013Inventor: Erard Gilles
-
Publication number: 20130089632Abstract: The present disclosure provides a cosmetic composition which includes at least one of Scutellaria baicalensis essence, licorice essence, and mixture of Scutellaria baicalensis extract and licorice extract as active ingredient and, optionally, further includes at least one of zinc pyrithione, panthenol and thuja semen extract. The cosmetic composition of the present disclosure is capable of inhibiting hair loss and enhancing hair growth by inhibiting binding with the androgen receptor and regulating the hair growth factor so as to induce transition from telogen to anagen and prolong anagen.Type: ApplicationFiled: April 5, 2012Publication date: April 11, 2013Applicant: AMOREPACIFIC CORPORATIONInventors: Byung Ha Kang, Woori Bae, Su Na Kim, Ah Reum Kim, Kyoung Mi Jung, Eun Joo Kim, John Hwan Lee
-
Publication number: 20130090591Abstract: A method for localizing delivery of an agent to a target site in a subject is provided. The method allows accumulation and/or release of the agent at the target site in the subject through the use of an energy source.Type: ApplicationFiled: March 1, 2011Publication date: April 11, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Katherine W. Ferrara, Azedah Kheirolomoom
-
Publication number: 20130090297Abstract: Compositions for the promotion of muscle protein synthesis and control of tumor-induced weight loss in patients that are, for example, suffering from cancer cachexia, and methods of administering such compositions.Type: ApplicationFiled: November 28, 2012Publication date: April 11, 2013Applicant: NESTEC S.A.Inventor: NESTEC S.A.
-
Publication number: 20130084345Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered with indibulin or a pharmaceutically acceptable salt thereof and the combination is synergistic. Another aspect of the invention relates to the treatment of cancer with indibulin as a single agent. Another aspect of the invention relates to dosing regimen for administration of oral dosage forms of indibulin.Type: ApplicationFiled: November 20, 2012Publication date: April 4, 2013Applicant: ZIOPHARM ONCOLOGY, INC.Inventor: Ziopharm Oncology, Inc.
-
Publication number: 20130078288Abstract: A method and composition for administering a therapeutic composition to a lesion comprising about 20% to about 50% ethanol and other novel therapeutic agents.Type: ApplicationFiled: November 20, 2012Publication date: March 28, 2013Inventor: Chun Ho Yu
-
Publication number: 20130078319Abstract: Among other things, the present disclosure provides a method including the steps of: obtaining a uterine sample; and detecting and/or characterizing in the uterine sample an ovarian cancer biomarker (e.g., CA125).Type: ApplicationFiled: September 22, 2012Publication date: March 28, 2013Applicant: Memorial Sloan-Kettering Cancer CenterInventor: Memorial Sloan-Kettering Cancer Center
-
Patent number: 8404650Abstract: The invention provides therapeutically effective compounds for the prevention and treatment of cancer and pharmaceutical compositions containing these compounds as well as methods of using and administering these compounds. The invention also includes methods of activating a prodrug of these therapeutically effective compounds by the administration of a peptide-directed targeting construct that delivers a prodrug-activating enzyme to a target activation site.Type: GrantFiled: October 30, 2006Date of Patent: March 26, 2013Assignee: The Regents of the University of Colorado, a body corporateInventors: Tad H. Koch, David J. Burkhart, Glen C. Post, Jordan W. Nafie, Brian T. Kalet, Benjamin L. Barthel, Daniel L. Rudnicki
-
Publication number: 20130071323Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.Type: ApplicationFiled: March 9, 2012Publication date: March 21, 2013Applicant: Gilead Calistoga LLCInventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese, Brian Lannutti, Langdon Miller, Thomas M. Jahn
-
Publication number: 20130064880Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.Type: ApplicationFiled: September 6, 2012Publication date: March 14, 2013Applicants: LES LABORATOIRES SERVIERInventors: Ioana Kloos, Renata Robert, Anne Jacquet-Bescond, Stéphane Depil, Marylore Chenel, Sylvain Fouliard, Sriram Balasubramanian
-
Publication number: 20130059806Abstract: This disclosure describes methods of screening for compounds that disrupt the interaction between DNMT1 and the gamma-globin promoter or between LSD-1 and the gamma-globin promoter. This disclosure describes methods of screening for compounds that de-repress the gamma-globin gene.Type: ApplicationFiled: May 24, 2012Publication date: March 7, 2013Inventors: James Douglas Engel, Osamu Tanabe, Lihong Shi
-
Publication number: 20130059015Abstract: Disclosed are identified and successfully targeted microRNAs (miRNAs) associated with human cancer cell line response to a range of anti-cancer agents. The strategy of integrating in vitro miRNA expression and drug sensitivity data not only aid in the characterization of determinants of cytotoxic response, but also in the identification of novel therapeutic targets.Type: ApplicationFiled: March 11, 2011Publication date: March 7, 2013Applicant: H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTEInventors: Johnathan Mark Lancaster, Yin Xiong, Ning Chen
-
Patent number: 8389697Abstract: The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.Type: GrantFiled: January 27, 2012Date of Patent: March 5, 2013Assignee: Genentech, Inc.Inventors: Italo Beria, Michele Caruso, John A. Flygare, Vittoria Lupi, Rita Perego, Paul Polakis, Andrew Polson, Matteo Salsa, Susan D. Spencer, Barbara Valsasina
-
Publication number: 20130045203Abstract: This disclosure relates to methods of treating or preventing cancer comprising administering a pharmaceutical composition comprising noscapine or noscapine derivatives to a subject diagnosed with a mutated adenomatous polyposis coli (APC) gene.Type: ApplicationFiled: February 25, 2011Publication date: February 21, 2013Applicant: EMORY UNIVERSITYInventors: Harish C. Joshi, Vincent Yang
-
Publication number: 20130045935Abstract: This invention relates to bis-flavonoid compounds of formula Flavonoid-Linker-Y-Linker-Flavonoid, their synthesis and use for inhibiting multidrug resistance in chemotherapy and protozoan infection.Type: ApplicationFiled: May 3, 2011Publication date: February 21, 2013Inventors: Tak-Hang Chan, Larry Ming-Cheung Chow, Kin-Fai Chan, Iris Lai King Wong
-
Publication number: 20130046275Abstract: A hydrophilic biocompatible sustained-release material is disclosed. The material comprises amounts of Pluronic F-127, PEG-400, HPMC and water, effective to produce a composition of sufficiently low viscosity at room temperature to be injectable into an internal body cavity via a tube inserted within a urinary catheter. At body temperature, the material exhibits a much higher viscosity and will stably adhere to the internal surface of a body cavity. As the material dissolves, a therapeutic agent incorporated therein is slowly released to the body cavity, while the material itself is excreted from the body.Type: ApplicationFiled: July 19, 2012Publication date: February 21, 2013Applicant: THERACOAT LTD.Inventors: Asher HOLZER, Dorit DANIEL, Michael MULLERAD, Jaime DE LA ZERDA, Uri SHPOLANSKY, Nadav MALCHI, Yosh DOLLBERG, Dor TAL, Yossi YAVIN, Marina KONORTY
-
Publication number: 20130039971Abstract: Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.Type: ApplicationFiled: July 23, 2012Publication date: February 14, 2013Applicant: OPKO OPHTHALMICS, LLCInventor: Nadine Dejneka
-
Publication number: 20130039906Abstract: Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: ApplicationFiled: August 10, 2012Publication date: February 14, 2013Inventors: Steven Do, Huiyong Hu, Aleksandr Kolesnikov, Wendy Lee, Vickie H. Tsui, Xiaojing Wang, Zhaoyang Wen
-
Publication number: 20130040905Abstract: The present invention relates to a composition and a combination comprising at least one first drug and at least one protein-binding prodrug, wherein the proteinbinding prodrug comprises a protein-binding group, a second drug, and a linker that can be cleaved hydrolytically, enzymatically, or in a pH-dependent manner in the body, as well as to a kit and a pharmaceutical composition comprising said composition or combination.Type: ApplicationFiled: April 13, 2011Publication date: February 14, 2013Applicant: KTB Tumorforschungsgesellschaft mbHInventor: Felix Kratz
-
Publication number: 20130039904Abstract: The present invention discloses a gamboge acid cyclization analogs, their preparation methods and applications by semi-synthesis with the following structural formula I-III: Where ring A, ring B or/and ring C is 4-10 membered saturated or/and unsaturated aliphatic ring aliphatic heterocycle or aryl heterocycle. R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 or/and R12 is, independently at each occurrence, optionally substituted substituent of glycosyl, multi-hydroxyl, amino acid, acyloxy, phosphoric acid oxy, sulfonyloxy, alkoxy, aryloxy, heterocyclic oxy, thiol, aliphatic or cyclic group containing oxygen, sulfur, nitrogen or phosphorus, one of the substituents or combinations thereof. The present invention has antitumor activity management, antiviral, antibacterial and antifungal activity management, as anti-tumor, anti-viral, immune, antibacterial and antifungal agents, with other known anti-tumor, anti-viral, immune, together with the application of antibacterial and antifungal.Type: ApplicationFiled: August 2, 2010Publication date: February 14, 2013Applicant: Liaoning Lifeng Scientific & Technology Development Company Ltd.Inventor: Lifeng Xu
-
Publication number: 20130040904Abstract: Methods for treating or preventing cardiomyopathy in a subject by administering an ?1 adrenergic receptor agonist, wherein the treatment does not result in increased blood pressure are provided.Type: ApplicationFiled: September 7, 2012Publication date: February 14, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Paul C. Simpson
-
Publication number: 20130029918Abstract: The present invention provides compositions for delivering highly water-soluble drugs (such as vinca alkaloids) and methods of using such compositions.Type: ApplicationFiled: June 21, 2012Publication date: January 31, 2013Applicant: Adventrx Pharmaceuticals, Inc.Inventor: Andrew Xian Chen
-
Publication number: 20130029926Abstract: The invention generally relates to a molecular classification of disease and particularly to molecular markers for cancer susceptibility and methods of use thereof. More specifically, the invention relates to the determination, screening, or classification of an individual's genetic risk for breast and ovarian cancer susceptibility.Type: ApplicationFiled: November 5, 2010Publication date: January 31, 2013Applicant: Myriad Genetics, Inc.Inventors: Kirsten Timms, Jennifer Potter, Jerry Lanchbury
-
Publication number: 20130029901Abstract: Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (RT), having an affinity for bone; a Bone Active Portion (RA) for interacting with and affecting bone; and a Linking Portion (RL) connecting the Bone Targeting Portion and the Bone Active Portion.Type: ApplicationFiled: July 30, 2012Publication date: January 31, 2013Inventors: William M. PIERCE, JR., K. Grant TAYLOR, Leonard C. WAITE, Kevyn MERTEN
-
Publication number: 20130028989Abstract: Targeting uncontrolled cell proliferation and resistance to DNA damaging chemotherapeutics with at least one reagent has significant potential in cancer treatment. Replication Protein A, the eukaryotic single-strand (ss) DNA binding protein, is essential for genomic maintenance and stability via roles in both DNA replication and repair. Reported herein are small molecules that inhibits the in vitro, in vivo, and cellular ssDNA binding activity of RPA, thereby disrupting the eukaryotic cell cycle, inducing cytotoxicity and increasing the efficacy of chemotherapeutic agents damage DNA, and/or disrupt its replication and/or function. These results provide new insights into the mechanism of RPA-ssDNA interactions in chromosome maintenance and stability. This represents a molecularly targeted eukaryotic DNA binding inhibitor and demonstrates the utility of targeting a protein-DNA interaction as a means of studying the cell cycle and providing a therapeutic strategy for cancer treatment.Type: ApplicationFiled: February 5, 2011Publication date: January 31, 2013Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventors: John J. Turchi, Sarah Shuck
-
Publication number: 20130029928Abstract: There is provided compositions comprising perfluorooctanoic acid (PFOA) or a salt, derivative or variant thereof. There is also provided uses, methods therapeutic systems and combination therapies relating to PFOA.Type: ApplicationFiled: February 18, 2011Publication date: January 31, 2013Inventors: Clifford Roy Elcombe, Charles Roland Wolf, Anna Louise Westwood
-
Publication number: 20130029927Abstract: The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.Type: ApplicationFiled: July 25, 2012Publication date: January 31, 2013Inventors: Peter Wisdom Atadja, Wenlin Shao, Kapil N. Bhalla
-
Patent number: 8361973Abstract: The present invention provides glycoside compounds, methods of preparing such compounds, pharmaceutical compositions comprising such compounds, and a method for the treatment of hyperproliferative diseases using the same.Type: GrantFiled: August 7, 2009Date of Patent: January 29, 2013Assignee: Centrose, LLCInventors: Mohammed S. Shekhani, James R. Prudent, Jill Hutchinson Bollettieri
-
Publication number: 20130022671Abstract: Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.Type: ApplicationFiled: July 17, 2012Publication date: January 24, 2013Inventors: Paul F. Glidden, Alison J. Pilgrim, Stephen R. Hanson
-
Patent number: 8357785Abstract: A method for the aralkylation of anthracyclins by utilizing an aralkylating agent R3—CH2X (for example, BnBr) in accordance with the reaction pathway describe by the scheme shown in FIG. 1. The present invention recognizes that 4-R1, 3?-N3-Daunomycines are suitable substrates for selective 4?-O-benzylation, yielding 4-R1, 3?-N3-4?-O-Aralkyl-Daunorubicines (in particular, 4?-O-Bn-Daunomycines). Thus, the present invention provides a pathway for a simple production of 4?-O-aralkylated derivatives of anthracyclines which can be effectively used to produce anthracyclines.Type: GrantFiled: May 23, 2008Date of Patent: January 22, 2013Assignee: Solux CorporationInventors: Alexander F. Zabudkin, Victor Matvienko, Alexey Matveev, Aleksandr M. Itkin
-
Publication number: 20130011445Abstract: Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles.Type: ApplicationFiled: July 12, 2012Publication date: January 10, 2013Inventors: Thomas C. Crawford, Scott Eliasof, Geeti Gangal, Pei-Sze Ng, Lawrence Alan Reiter
-
Publication number: 20130012465Abstract: The present invention relates to a method of treating patients suffering from triple negative breast cancer comprising administration of an effective amount of the irreversible EGFR/HER1 and HER2 inhibitor BIBW 2992 (1) to a person in need of such treatment, optionally in combination with the administration of a further chemotherapeutic agent (2), in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery.Type: ApplicationFiled: December 6, 2010Publication date: January 10, 2013Applicant: Boehringer Ingelheim International GmbHInventors: Christian Haslinger, Flavio Solca, Martina Uttenreuther-Fischer
-
Publication number: 20130011365Abstract: The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy-induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radio sensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects.Type: ApplicationFiled: June 19, 2012Publication date: January 10, 2013Applicant: EISAI INC.Inventors: Weizheng XU, Greg Delahanty, Ling Wei, Jie Zhang
-
Publication number: 20130011467Abstract: This invention is directed to methods of treating solid tumor cancers, particularly refractory cancers by administration of two pluralities of microparticles, one comprising drug-carrying microparticles sized to lodge at the tumor preferably in the capillary bed of the tumor and the other comprising non-drug-carrying microparticles sized to lodge in the arterial system servicing the tumor so as to embolize the tumor.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicant: Abbott Cardiovascular Systems Inc.Inventors: Liangxuan Zhang, Florencia Lim
-
Publication number: 20130012466Abstract: Colchicine neoglycosides, method for their synthesis and methods for their use are disclosed. The invention provides analogs of colchicine glycosylated to include a sugar moiety on a colchicine scaffold that is generally unglycosylated in nature. The colchicine neoglycosides disclosed herein are shown to have cytotoxic effects equivalent to at least the known cytotoxins paclitaxel and doxorubicin. Further, the neoglycosides disclosed according to the invention have physiologic effects not previously recognized in the alkaloid family that includes colchicine but recognized in other cytotoxic drug families such as the taxanes which act by stabilizing tubulin formation.Type: ApplicationFiled: July 9, 2012Publication date: January 10, 2013Applicant: Wisconsin Alumni Research FoundationInventors: Jon S. Thorson, Ahmed Aqeel
-
Publication number: 20130004427Abstract: The invention provides for dendrimer conjugates useful for liver-specific delivery of therapeutic agents. The therapeutic agent is associated to the dendrimer through a enzyme-cleavable covalent linkage.Type: ApplicationFiled: June 11, 2012Publication date: January 3, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Mohamed E.H. El-Sayed, William Ensminger, Donna Shewach
-
Patent number: 8343943Abstract: Disclosed herein is a cancer sensitizer comprising glucosamine, a glucosamine derivative, or a salt thereof. When administered to patients with cancer, the cancer sensitizer functions to sensitize cancer cells to anticancer agents without producing side effects, thereby increasing the therapeutic efficiency of chemotherapy.Type: GrantFiled: December 6, 2006Date of Patent: January 1, 2013Assignee: National Cancer CenterInventors: Soo Youl Kim, Dae Seok Kim
-
Patent number: 8343511Abstract: The present disclosure provides improved compositions comprising rifabutin, clarithromycin, and clofazimine for use in the treatment of Inflammatory Bowel Diseases. In one instance, the compositions may comprise a formulation of rifabutin, clarithromycin, and clofazimine in a single dosage form, such as a capsule, tablet, etc., with one or more specific excipients.Type: GrantFiled: February 5, 2009Date of Patent: January 1, 2013Assignee: Red Hill Biopharma Ltd.Inventors: Thomas Julius Borody, Patrick Gosselin
-
Publication number: 20120328610Abstract: The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors: Formula (I), in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis proliferative of diseases, as well as to intermediate compounds useful in the preparation of said compounds.Type: ApplicationFiled: November 17, 2010Publication date: December 27, 2012Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Volker Schulze, Marcus Koppitz, Dirk Kosemund, Hartmut Schirok, Benjamin Bader, Philip Lienau, Antje Margret Wengner, Hans Briem, Simon Holton, Gerhard Siemeister, Stefan Prechtl, Ulf Bömer
-
Publication number: 20120328691Abstract: The present invention relates to novel Anilinopiperazine Derivatives of Formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, cancer, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.Type: ApplicationFiled: October 29, 2007Publication date: December 27, 2012Inventors: Gerald W. Shipps, JR., Cliff C. Cheng, Xiaohua Huang, Thierry O. Fischmann, Jose S. Duca, Matthew Richards, Hongbo Zeng, Binyuan Sun, Panduranga Adulla Reddy, Tzu T. Wong, Praveen K. Tadikonda, M. Arshad Siddiqui, Marc A. Labroli, Cory Poker, Timothy J. Guzi
-
Publication number: 20120329744Abstract: Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions.Type: ApplicationFiled: June 25, 2012Publication date: December 27, 2012Inventors: William A. Garland, Brian D. Frenzel
-
Publication number: 20120329712Abstract: This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents.Type: ApplicationFiled: June 5, 2012Publication date: December 27, 2012Applicant: University of Southern CaliforniaInventor: Valter Longo
-
Publication number: 20120328705Abstract: A magnetic nanomedicine for tumor suppression and therapy, comprising: a core, made of magnetic nanoparticles; a shell, encapsulating said core and is made of carboxylated polyaniline (SPAnH); and a tumor suppression medicine Epirubicin (EPI) or Doxorubicin (DOX) covalently bonded onto said shell. Said magnetic nanomedicine is capable of improving its thermal stability, and it can be dissolved uniformly in water, plus its superparamagnetic property, thus it can be guided by an outside magnetic field to concentrate to the site of tumor distribution to increase the local medicine concentration and enhance therapy effect.Type: ApplicationFiled: June 22, 2011Publication date: December 27, 2012Inventors: Mu-Yi Hua, Hong-Wei Yang, Cheng-Keng Chuang, See-Tong Pang, Rung-Ywan Tsai, Kun-Lung Chuang